Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Acute therapies continue to report strong growth compared to chronic ones.
The list of kids with co-morbidities eligible for vaccination would be announced by the government
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Subscribe To Our Newsletter & Stay Updated
